Sun to divest anticonvulsant to Torrent under FTC terms
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industrieshas agreed to divest certain assets relating to the anticonvulsant carbamazepine, a generic version of Novartis's Tegretol, as part of the terms specified by the US Federal Trade Commission(FTC) for approving Sun's acquisition ofTaro Pharmaceutical Industries. The commission has approved the Indian company Torrent Pharmaceuticals as the up-front purchaser of these assets.